How has been the historical performance of Bacil Pharma?

Answer:The historical performance of Bacil Pharma shows a consistent trend of zero net sales and other operating income from March 2019 to March 2025. The total operating income remained at zero throughout this period, with the only notable expense being employee costs, which increased slightly from 0.05 crore in March 2021 to 0.14 crore in March 2025. The total expenditure, excluding depreciation, peaked at 3.92 crore in March 2022 but has since decreased to 0.25 crore by March 2025. Operating profit (PBDIT) was negative across all years, with a significant loss of 3.92 crore in March 2022, improving to a positive 0.41 crore in March 2025. Profit after tax also turned positive in March 2025 at 0.40 crore, a significant recovery from losses in previous years. The company's total assets increased dramatically from 1.27 crore in March 2024 to 25.55 crore in March 2025, primarily due to a rise in non-current investments. Cash flow from financing activities showed a positive inflow of 2.00 crore in March 2025, contributing to a closing cash balance of 2.00 crore.

Breakdown:
Bacil Pharma's financial performance over the years reflects a lack of revenue generation, with net sales and operating income consistently recorded at zero from March 2019 to March 2025. Employee costs have gradually increased, indicating some operational activity, while total expenditure saw a significant drop from 3.92 crore in March 2022 to 0.25 crore in March 2025. Despite ongoing losses in operating profit until March 2024, the company achieved a turnaround in March 2025, reporting a positive operating profit of 0.41 crore and a profit after tax of 0.40 crore. The total assets surged to 25.55 crore in March 2025, driven by a substantial increase in non-current investments, while cash flow from financing activities turned positive, resulting in a closing cash balance of 2.00 crore. This indicates a potential recovery phase for Bacil Pharma after several years of financial challenges.